<DOC>
	<DOCNO>NCT02849249</DOCNO>
	<brief_summary>The study design accord draft allergenic product regulation publish Spanish Regulatory Agency . The aim study evaluate safety tolerability subcutaneous immunotherapy polimerized ( 100/100 ) mixture pollen : Olea europaea Phleum pratense patient rhinoconjunctivitis without associate mild asthma . In addition , surrogate efficacy parameter evaluate : immunoglobulin level change skin reactivity .</brief_summary>
	<brief_title>A Trial With Subcutaneous Immunotherapy ( SCIT ) Patients With Rhinoconjunctivitis Sensitized Olea Europaea Phleum Pratense</brief_title>
	<detailed_description />
	<criteria>1 . Patients must sign Informed Consent Form . 2 . Patients must 18 60 year age . 3 . Patients seasonal allergic rhinoconjunctivitis produce Phleum pratense Olea europaea least 2 year prior participate study . Although pathology study allergic rhinoconjunctivitis , patient concomitant mild moderate asthma may include . 4 . Patients skin prick test result ≥ 3 mm diameter Phleum pratense Olea europaea . 5 . Patients specific IgE ≥ class 2 ( CAP/PHADIA ) Phleum pratense Olea europaea . 6 . Patients preferably polysensitized Phleum pratense . Polysensitized patient otherallergenic source may include study sensitization produce : 1 . Overlapping seasonal pollen crossreactive Phleum pratense Olea europaea . 2 . Pollens whose season overlap Phleum pratense Olea europaea expect produce symptom study period . 3 . Other allergen expect produce symptom study period . 7 . Women childbearing potential must negative urine pregnancy test time begin study . 8 . Furthermore , woman childbearing potential must agree use adequate contraceptive method study sexually active . 1 . Patients receive immunotherapy previous 5 year Phleum pratense Olea europaea allergen cross reactivity patient currently receive immunotherapy allergen . 2 . Patients severe asthma forzed expiratoy volumen 1 second FEV1 &lt; 70 % even pharmacologically control . 3 . Patients : immunological , cardiac , renal hepatic illness medical condition investigator deem relevant interfere study . 4 . Patients previous history anaphylaxis 5 . Patients chronic urticaria , 6 . Patients moderate severe atopic dermatitis 7 . Patients participate another clinical trial within 3 month prior enrolment . 8 . Patients treatment tricyclic antidepressives , phenothiazine , β blocker , Angiotensin Converting Enzyme Inhibitors ( ACEI ) 9 . Female patient pregnant breastfeed 10 . Patient attend visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>allergy</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>SCIT</keyword>
</DOC>